KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Operating Margin (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Operating Margin for 9 consecutive years, with 64.05% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Margin rose 6747.0% year-over-year to 64.05%, compared with a TTM value of 38.98% through Dec 2025, up 3954.0%, and an annual FY2025 reading of 38.98%, up 3954.0% over the prior year.
  • Operating Margin was 64.05% for Q4 2025 at Biocryst Pharmaceuticals, up from 18.56% in the prior quarter.
  • Across five years, Operating Margin topped out at 64.05% in Q4 2025 and bottomed at 28.31% in Q4 2023.
  • Average Operating Margin over 3 years is 9.18%, with a median of 8.01% recorded in 2024.
  • Peak annual rise in Operating Margin hit 6747bps in 2025, while the deepest fall reached 1022bps in 2025.
  • Year by year, Operating Margin stood at 28.31% in 2023, then skyrocketed by 88bps to 3.43% in 2024, then surged by 1969bps to 64.05% in 2025.
  • Business Quant data shows Operating Margin for BCRX at 64.05% in Q4 2025, 18.56% in Q3 2025, and 18.23% in Q2 2025.